Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from BioNano Genomics ( (BNGO) ).
On May 14, 2026, Bionano Genomics, Inc. held its 2026 Annual Meeting of Stockholders, with 4,225,995 shares represented, or about 38.1% of shares outstanding and entitled to vote as of the March 19, 2026 record date. Shareholders elected Albert Luderer and Kristiina Vuori as Class II directors to serve until the 2029 annual meeting, or until earlier departure events.
Investors also approved on an advisory basis the compensation of the company’s named executive officers, reflecting support for current executive pay practices. In addition, stockholders ratified the selection of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026, reinforcing continuity in the company’s financial oversight framework.
The most recent analyst rating on (BNGO) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on BioNano Genomics stock, see the BNGO Stock Forecast page.
Spark’s Take on BNGO Stock
According to Spark, TipRanks’ AI Analyst, BNGO is a Neutral.
The score is held down primarily by weak financial performance (shrinking TTM revenue, large losses, and negative free cash flow), with only partial offset from the earnings call’s improved commercialization signals (consumables growth, margin progress, and reaffirmed guidance). Technicals are neutral-to-mixed and do not provide strong confirmation, valuation metrics offer little support for a loss-making company, and the recent CEO transition adds incremental execution risk.
To see Spark’s full report on BNGO stock, click here.
More about BioNano Genomics
Bionano Genomics, Inc. operates in the genomics and life sciences industry, focusing on technologies for genome analysis and structural variation detection. Its tools and services are used by researchers and clinicians seeking high-resolution insights into genetic disorders, cancer, and other diseases, positioning the company within the precision medicine and advanced diagnostics market.
Average Trading Volume: 285,275
Technical Sentiment Signal: Sell
Current Market Cap: $13.98M
Find detailed analytics on BNGO stock on TipRanks’ Stock Analysis page.